Glesatinib is primarily used in the field of oncology as a targeted therapy for certain types of cancer. It functions as a dual inhibitor of MET and AXL, which are receptor tyrosine kinases involved in cancer cell growth, survival, and metastasis. This makes it particularly effective in treating cancers where these pathways are dysregulated, such as non-small cell lung cancer (NSCLC). By inhibiting these receptors, Glesatinib helps to slow down or stop the progression of cancer, offering a more tailored treatment option for patients with specific genetic mutations or alterations. Its application is often explored in clinical trials to assess its efficacy and safety in various cancer types, potentially providing a new therapeutic avenue for patients who may not respond well to conventional treatments.